Obesity rates in the United States have finally started to show a decline, heading in the right direction for the first time in a decade likely due to the popularity of weight loss drugs like Ozempic.

2023 marked a decline in BMI and obesity prevalence in the US, potentially linked to weight loss medications like semaglutide. The study analyzed data from 16,743,822 adults, showing a slight BMI ...

The obesity rate among U.S. adults fell in 2023 for the first time in over a decade, according to a new study released on Friday. The study published in the journal JAMA Health Forum found that ...

For the first time in over a decade, obesity rates in the United States may finally be heading in the right direction and new weight loss drugs like semaglutide could be part of the reason why.

For the first time in a decade, obesity in the US is declining — and a new study suggests it’s because of wildly popular medications such as Ozempic. The number of obese Americans has been ...

Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with ...